AstraZeneca Acquires Dogma Therapeutics’ Oral PCSK9 Inhibitor Program

 AstraZeneca Acquires Dogma Therapeutics’ Oral PCSK9 Inhibitor Program

AstraZeneca Acquires Dogma Therapeutics’ Oral PCSK9 Inhibitor Program

Shots:

  • Dogma to receive upfront along with global regulatory and commercial milestones. AstraZeneca to get the rights to an orally active drug inhibiting PCSK9, offering a patient-friendly alternative to current cholesterol-lowering therapies that are delivered via a needle
  • The agreement allows the AstraZeneca to develop the first small molecule, orally bioavailable PCSK9 inhibitor for patients at risk of cardiovascular disease
  • PCSK9 is considered the exemplary target accredited by human genetics, as variants found in humans establish the needed directionality of a therapeutic

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Clariba

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post